The mixed readout creates a binary catalyst dynamic: FB102's Phase 2 success supports pipeline optionality in celiac disease (no approved therapies), but the UNITY Phase 3 failure in Sjögren's removes a key late-stage program. Watch for detailed Phase 2 data at upcoming medical meetings and Phase 3 initiation timeline for FB102.
Price Chart
Executive Summary
argenx reported positive Phase 2 topline results for FB102 in celiac disease, meeting the primary endpoint (p=0.0176) and plans to advance to Phase 3, while simultaneously announcing discontinuation of the Phase 3 UNITY study of efgartigimod SC in Sjögren's disease due to futility. The mixed news balances a promising pipeline candidate against a setback in a key late-stage program.
Key Facts
- Phase 2 study of FB102 in celiac disease met primary endpoint of change from baseline in Vh:Cd ratio (p=0.0176).
- argenx plans to advance FB102 into Phase 3 development.
- Phase 3 UNITY study of efgartigimod SC in Sjögren's disease discontinued for futility following IDMC recommendation.
- No new safety signals identified in either study.
- FB102 is a first-in-class CD122 inhibitor acquired via Forte Biosciences acquisition in August 2026.
- FB102 has FDA Fast Track Designation for celiac disease.
- FB102 is also being evaluated in vitiligo and alopecia areata.
Financial Impact
No financial figures provided; FB102 Phase 2 success opens a new pipeline opportunity in a large untreated market (celiac disease ~1% global prevalence), while UNITY failure removes a potential Sjögren's revenue stream.
Risk Factors
- Phase 3 failure in Sjögren's may dampen sentiment on efgartigimod's broader pipeline potential.
- FB102 is still early-stage; Phase 3 risk remains for celiac disease.
- No financial guidance or revenue impact disclosed in the filing.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-114491 |
| Document: tm2627263d1_ex99-2.htm | 0001104659-26-114491 |
| Document: tm2627263d1_6k.htm | 0001104659-26-114491 |
| Document: 0001104659-26-114491-index-headers.html | 0001104659-26-114491 |
| Document: 0001104659-26-114491-index.html | 0001104659-26-114491 |
| Document: 0001104659-26-114491.txt | 0001104659-26-114491 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $875.76 | awaiting T+20 | — | $882.48 (+0.77%) |
Oct 19, 2026 8d ago | 6-K | $825.61 | awaiting T+20 | — | $882.48 (+6.89%) |
Oct 8, 2026 19d ago | 6-K | $818.63 | awaiting T+20 | — | $882.48 (+7.80%) |
Sep 29, 2026 28d ago | 6-K | $970.66 $871.52 | ▼ −10.21% | ▼ −10.87% | $882.48 (−9.08%) |
Sep 10, 2026 6w ago | Institutional Cluster | $984.04 $818.63 | ▼ −16.81% | ▼ −18.93% | $882.48 (−10.32%) |
Aug 17, 2026 10w ago | 6-K | $987.84 $990.54 | ▲ +0.27% | ▲ +1.80% | $882.48 (−10.67%) |
Aug 6, 2026 11w ago | Press Release | $875.30 $1,053.46 | ▲ +20.35% | ▲ +19.75% | $882.48 (+0.82%) |
Jul 27, 2026 13w ago | 6-K | $888.82 $1,011.11 | ▲ +13.76% | ▲ +10.46% | $882.48 (−0.71%) |
Jul 27, 2026 13w ago | Press Release | $888.82 $1,011.11 | ▲ +13.76% | ▲ +10.46% | $882.48 (−0.71%) |
Jul 23, 2026 13w ago | Press Release | $924.60 $1,038.12 | ▲ +12.28% | ▲ +8.97% | $882.48 (−4.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers